Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London, EC4N 7BL, UK
Prochlorperazine Mesilate 12.5mg/ml Solution for Injection.
| Pharmaceutical Form |
|---|
|
Colourless or almost colourless sterile solution for injection intended for parenteral administration to human beings. |
Each 1ml of solution contains 12.5mg (1.25% w/v) of Prochlorperazine Mesilate.
| Active Ingredient | Description | |
|---|---|---|
| Prochlorperazine |
Prochlorperazine belongs to the phenothiazine group. Prochlorperazine has a wide range of activity arising from its depressant actions on the CNS and its alpha-adrenergic blocking and weaker anti-muscarinic properties. It inhibits dopamine and prolactin-release-inhibitory factor, thus stimulating the release of prolactin. |
| List of Excipients |
|---|
|
Sodium sulphite B.P. |
1ml and 2ml clear One Point Cut (OPC) glass ampoules, glass type 1 Ph.Eur. packed in cardboard cartons to contain 5x 1ml; 5 × 2ml; 10 × 1ml and 10 × 2ml ampoules.
Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London, EC4N 7BL, UK
PL 12762/0599
14/07/1992 / 27/02/2009
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
